Biomedicines to reduce inflammation but not viral load in chronic HCV - What's the sense?

Trends in Biotechnology

Volumn 22, Issue 10, 2004, Pages 517-523

  Chuang, Emil ^a   Vecchio, Alfred Del ^a   Smolinski, Steve ^a   Song, Xiao Yu ^a   Sarisky, Robert T ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICINES; CYTOKINES; VIRAL PATHOGENS;

BIOLOGICAL ORGANS; DISEASES; PATHOLOGY; TISSUE; VIRUSES;

MEDICINE;

ANTIVIRUS AGENT; CYTOKINE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; CELL ACTIVITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG MECHANISM; FIBROSIS; HEALING; HEPATITIS C; HEPATITIS C VIRUS; HOST RESISTANCE; HUMAN; INFLAMMATION; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCAR; TISSUE INJURY; VIRUS LOAD;

ANTIBODIES, MONOCLONAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LIVER CIRRHOSIS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 4644370343     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2004.08.011     Document Type: Review

References (78)

1. S.L. Friedman Liver fibrosis - from bench to bedside J. Hepatol. 38 2003 S38 S53
2. J. Wu, and M.A. Zern Hepatic stellate cells: a target for the treatment of liver fibrosis J. Gastroenterol. 35 2000 665 672
3. M.G. Neuman Tumor necrosis factor-α and transforming growth factor-β reflect severity of liver damage in primary biliary cirrhosis J. Gastroenterol. Hepatol. 17 2002 196 202
4. Q.L. Choo Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 1989 359 362
5. M.J. Alter The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 New Engl. J. Med. 341 1999 556 562
6. V. Lohmann Processing pathways of the hepatitis C virus proteins J. Hepatol. 24 1996 11 19
7. M.J. Koziel Cytokines in viral hepatitis Semin. Liver Dis. 19 1999 157 169
8. A.J. Freeman Immunopathogenesis of hepatitis C virus infection Immunol. Cell Biol. 79 2001 515 536
9. R. Thimme Viral and immunological determinants of hepatitis C virus clearance, persistence and disease Proc. Natl. Acad. Sci. U. S. A. 99 2002 15661 15668
10. + T cells in chronic hepatitis C virus infection J. Immunol. 169 2002 3447 3458
11. G. Ballardini Hepatitis C virus genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C J. Clin. Invest. 95 1995 2067 2075
12. K. Krawczynski Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification Gastroenterol. 103 1992 622 629
13. B. Rehermann Differential cytotoxic T-lymphocyte responsiveness to the hepatitis BC viruses in chronically infected patients J. Virol. 70 1996 7092 7102
14. D.R. Nelson The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C J. Immunol. 158 1997 1473 1481
15. K.M. Chang Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C J. Immunol. 162 1999 1156 1164
16. D. Kagi Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity Science 265 1994 528 530
17. M.Y. Braun Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease J. Exp. Med. 183 1996 657 661
18. M.J. Koziel HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release J. Clin. Invest. 96 1995 2311 2321
19. H. Kita A minimal and optimal cytotoxic T cell epitope within hepatitis C virus nucleoprotein J. Gen. Virol. 76 1995 3189 3193
20. M.J. Koziel Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis J. Immunol. 149 1992 3339 3344
21. K. Ando Perforin, Fas/Fas ligand, and TNF-α pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL J. Immunol. 158 1997 5283 5291
22. N. Kinnman In situ expression of transforming growth factor beta1-3, latent transforming growth factor beta-binding protein and tumor necrosis factor-alpha in liver tissue from patients with chronic hepatitis C Scand. J. Gastroenterol. 35 2000 1294 1300
23. A. Bertoletti, and M.K. Maini Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr. Opin. Immunol. 12 2000 403 408
24. Beyaert, R. and Beutler, B. (1996) The tumor necrosis factor and lymphotoxin. In Cytokines, pp. 335-359, Academic Press.
25. R.P. Woitas HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C World J. Gastroenterol. 8 2002 562 566
26. M.G. Neuman Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C Clin. Biochem. 34 2001 173 182
27. F.L. Dumoulin Intrahepatic mRNA levels of interferon-γ and tumor necrosis factor-α and response to antiviral treatment of chronic hepatitis C J. Hum. Virol. 4 2001 195 199
28. E. Larrea Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C Hepatology 23 1996 210 217
29. M.P. Manns Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
30. M.W. Fried Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection New Engl. J. Med. 347 2002 975 982
31. L. Llorent Cytokine gene expression in cirrhotic and noncirrhotic human liver J. Hepatol. 24 1996 555 563
32. F.L. Dumoulin Semiquantitative analysis of intrahepatic cytokine mRNAs in chronic hepatitis C J. Infect. Dis. 175 1997 681 685
33. R. Gonzalez-Amaro Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis J. Exp. Med. 179 1994 841 848
34. M. Toyoda Role of serum soluble Fas/soluble Fas ligand and TNF-α on response to interferon-a therapy in chronic hepatitis C Liver 20 2000 305 311
35. M.G. Neuman Serum tumor necrosis factor-α and transforming growth factor-β levels in chronic hepatitis C patients are immunomodulated by therapy Cytokine 17 2002 108 117
36. D. Lio IL-10 and TNF-α polymorphisms and the recovery from HCV infection Hum. Immunol. 64 2003 674 680
37. U. Schiemann Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism Digestion 68 2003 1 4
38. H.R. Rosen Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C Am. J. Gastroenterol. 97 2002 714 720
39. F.V. Chisari Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis Curr. Top. Microbiol. Immunol. 206 1996 149 173
40. A. Franco Pathogenic effector function of CD4-positive T helper 1 cells in hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice J. Immunol. 159 1997 2001 2008
41. Y. Kawanishi Tumor necrosis factor-alpha and interferon-gamma inhibit synergistically viral replication in hepatitis B virus-replicating cells J. Med. Virol. 47 1995 272 277
42. V. Pasquetto Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures J. Virol. 76 2002 5646 5653
43. K. Kimura Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice J. Immunol. 169 2002 5188 5195
44. S. Kasahara Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes J. Virol. 77 2003 2469 2476
45. I. Shimizu Antifibrogenic therapies in chronic HCV infection Curr. Drug Targets Infect. Disord. 1 2001 227 240
46. J.G. McHutchinson, and K. Patel Future therapy of hepatitis C Hepatology 36 2002 S245 S252
47. K. Kimura Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A Int. Immunol. 11 1999 1491 1500
48. F. Gantner Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor Hepatology 21 1995 190 198
49. R. Ksontini Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis J. Immunol. 160 1998 4082 4089
50. C. Orfila Expression of TNF-alpha and immunohistochemical distribution of hepatic macrophage surface markers in carbon tetrachloride-induced chronic liver injury in rats Histochem. J. 31 1999 677 685
51. P.P. Simeonova The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride Toxicol. Appl. Pharmacol. 177 2001 112 120
52. P. Muriel Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat Eur. J. Gastroenterol. Hepatol. 15 2003 951 957
53. K.L. Valentino First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes Int. J. Clin. Pharmacol. Ther. 41 2003 441 449
54. J.P. Iredale Cirrhosis: new research provides a basis for rational and targeted treatments Br. Med. J. 327 2003 143 147
55. D.R. Nelson Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial in interferon nonresponders Gastroenterology 118 2000 655 660
56. D.R. Nelson Long-term interleukin-10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect Hepatology 38 2003 859 868
57. M. Berenguer Hepatitis C and liver transplantation J. Hepatol. 35 2001 666 678
58. G.W. McCaughan, and A. Zekry Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection Transpl. Infect. Dis. 2 2000 166 185
59. L.G. Criscione, and E.W. St Clair Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases Curr. Opin. Rheumatol. 14 2002 204 211
60. D.E. Furst Recapitulation of the round-table discussion - assessing the role of anti-tumor necrosis factor therapy in the treatment of rheumatoid arthritis Rheumatol. 38 1999 50 53
61. J. Keane Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent New Engl. J. Med. 345 2001 1098 1104
62. L. Biancone Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection Gastroenterology 122 2002 593 594
63. S. Campbell, and S. Ghosh Infliximab treatment for Crohn's disease in the presence of chronic hepatitis C infection Eur. J. Gastroenterol. Hepatol. 13 2001 191 192
64. J.R. Peterson Effect of tumor necrosis factor-α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection Ann. Rheum. Dis. 62 2003 1078 1082
65. S. Magrin Hepatitis C viremia in chronic liver disease: relationship to interferon alpha or corticosteroid treatment Hepatology 19 1994 273 279
66. F. Hong Tumor necrosis factor-α attenuates interferon-α signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy FASEB J. 15 2001 1595 1597
67. T. Poynard Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
68. G.M. Lauer, and B.D. Walker Hepatitis C virus infection New Engl. J. Med. 345 2001 41 52
69. T. Poynard Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C J. Hepatol. 34 2001 730 739
70. K. Hino Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C J. Viral Hepat. 9 2002 370 376
71. L. Serfaty Determinants of outcome of compensated hepatitis C virus-related cirrhosis Hepatology 27 1998 1435 1440
72. Y. Shiratori Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy Ann. Intern. Med. 132 2000 517 524
73. K. Ishak Histological grading and staging of chronic hepatitis J. Hepatol. 22 1995 696 699
74. R.G. Knodell Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1 1981 431 435
75. M.G. Ghany Progression of fibrosis in chronic hepatitis C Gastroenterology 124 2003 97 104
76. W.M. Rosenberg Rating fibrosis progression in chronic liver diseases J. Hepatol. 38 2003 357 360
77. D. Thabut Noninvasive prediction of fibrosis in patients with chronic Hepatitis C Hepatology 37 2003 1220 1221
78. N.H. Afdhal Diagnosing fibrosis in Hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 37 2003 972 974